2025-12-08 – Press Releases – www.prnewswire.com
MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead…
